Astrazeneca Phar
ASTRAZEN • Pharmaceuticals & Biotechnology
Last Price
₹5970.50
Market Cap
₹14.93K Cr
Sector
Pharmaceuticals & Biotechnology
For educational/research use only. Not a recommendation to buy or sell.
At a glance
as of 2026-10-16Sector: Astrazeneca Phar (ASTRAZEN) is an NSE-listed company in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry. NSE sector rotation chart
Sharia rating: Astrazeneca Phar is rated Halal by a specialist third-party provider. Full list of halal NSE stocks
39% below its 52-week high
Price trend
Strongly negative
Over the last 6 months, Astrazeneca Phar's share price has fallen, doing better than 2% of Pharmaceuticals & Biotechnology stocks.
Institutional activity
Neutral
Trading patterns over recent weeks show no clear sign of institutions buying or selling Astrazeneca Phar (buying score 2/10, selling score 1/10).
Model rank
Positive
Our model's 5-day return score puts Astrazeneca Phar ahead of 79% of NSE stocks. The model is only moderately confident (57%).
Ease of trading
Low
Shares change hands easily; there are no signs of trading drying up (risk score 1/10).
Price vs profits
Well above typical
The share price is 80× last year's profit per share — well above the typical range for NSE stocks (15–30×).
The wider Indian market is in a crisis regime — unusually sharp moves (model 99% sure). This affects every stock's model rank.
Browse ready-made screens →Company Information
About Astrazeneca Phar (ASTRAZEN)
Astrazeneca Phar is an NSE-listed company operating in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry (ISIN INE203A01020). This page brings together the quantitative research signals our models compute for ASTRAZEN: a model-estimated 1-day, 5-day and 21-day return outlook, momentum and trend indicators, institutional-activity context derived from observed trading flows, a snapshot of valuation and quality fundamentals, and the instrument's Sharia-compliance status. All figures are produced by statistical models from historical data and are intended for research and educational purposes.
To read the page, treat the model-estimated return outlook as a relative ranking signal rather than a forecast of price — higher scores reflect stronger model-estimated momentum and trend alignment, not a target or guarantee. The momentum and trend indicators describe how Astrazeneca Phar's recent price action compares with its own history, while the fundamentals and institutional-activity context add longer-horizon and flow-based perspective. Nothing here is investment advice, a recommendation, or a solicitation to transact; always do your own research and consult a SEBI-registered adviser before making any decision.
The "typical range" we compare a price-to-earnings multiple against is a fixed band for all NSE stocks, not a sector-specific one. Everything on this page describes what our models measured; none of it is a recommendation to do anything.